Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LSL.V
Strong SellSinkerLSL Pharma Group Inc. · Healthcare · Canada · $30M · Avg Vol: $11K/d
15
StockRankGet insider-trade alerts
Q
26
V
37
M
30
P/E (TTM)
—
ROE
-31.6%
D/E
2.3x
Dividend %
—
COMPANY DESCRIPTION
LSL Pharma Group Inc. develops, manufactures, and commercializes sterile pharmaceutical products, cosmetic products, and natural health products in Canada, the United States, and internationally.
FINANCIAL SUMMARY (CAD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 8.2M | 10.0M | 17.7M | 28.7M | 51.8% | 41.6M |
| EPS (CAD) | -0.10 | -0.11 | 0.03 | -0.02 | — | -0.04 |
| Shares | 82.2M | 82.4M | 115.5M | 126.7M | +54.1% | 126.7M |
| Debt | 14.9M | 16.3M | 21.9M | 38.4M | 37.2% | 50.4M |
| Equity | 5.3M | 8.7M | 24.9M | 27.0M | 72.1% | — |
| Op CF | -3.2M | -7.1M | -1.7M | -2.4M | — | -5.8M |
| Inv CF | -1.0M | -1.0M | -7.5M | -7.5M | — | — |
| Fin CF | 3.4M | 8.1M | 9.4M | 10.2M | — | — |
Loading 1Y...
PRICE (1Y)-8.3%
SMA 50SMA 200
Close
$0.2385
RSI (14)
30.4
52W High
$0.4047
From 52W High
0.6%
SCORE BREAKDOWN
Quality
26
ROIC
-3.9%43.5
ROE
-31.6%26.8
GP/Assets
6.9%22.4
Op. Margin
-7.5%30.2
FCF/Assets
-14.3%27.4
Piotroski
316.9
Int. Cover
-0.8x37.0
D/E Ratio
2.30x4.6
Current Ratio
1.16x15.5
Value
37
P/E (TTM)
—N/A
EV/EBITDA
-55.9x25.0
P/FCF
—N/A
P/B
1.7x68.0
P/S
1.0x83.9
Div Yield
—N/A
Momentum
30
52W High %
59%34.0
RS 6M
-26%28.2
SMA 50/200
0.89x30.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$30M
P/E (Forward)
—
Gross Margin
12.4%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LSL.V are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LSL.V | LSL Pharma Group Inc.(you) | $30M | 15 | Strong Sell |
| OPTI.CN | Optimi Health Corp. | $27M | 12 | Strong Sell |
| VM.V | Voyageur Pharmaceuticals Ltd. | $28M | 19 | Strong Sell |
| MLCO.CN | The More Life Company Corp. | $26M | 23 | Sell |
| NVRS.CN | Noveris Health Sciences Inc. | $55M | 3 | Strong Sell |
| ROMJ.V | Rubicon Organics Inc. | $29M | 53 | Hold |
| LEEF.CN | Leef Brands Inc. | $58M | 42 | Hold |
| CRDL | Cardiol Therapeutics Inc. | $227M | 23 | Sell |
| CGC | Canopy Growth Corporation | $475M | 19 | Strong Sell |
| TLRY | Tilray Brands, Inc. | $631M | 13 | Strong Sell |
Peer medians: ROE -37.9% · P/E 17.3x · Gross margin 45.1%